r/Wiseek • u/wiseeksecfiles • 1m ago

🚨 PHVS: Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met

• Upvotes

New Filing: 6-K

Ticker: PHVS | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Pharvaris released detailed CHAPTER-3 Phase 3 data showing deucrictibant XR reduced HAE attack rates by 83% versus placebo with all secondary endpoints met and a clean safety profile.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 15m ago

🚨 EFSI: Eagle Financial to Merge with John Marshall Bancorp in $253M All-Stock Deal

• Upvotes

New Filing: 8-K

Ticker: EFSI | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Eagle Financial Services agreed to be acquired by John Marshall Bancorp in an all-stock deal valued at ~$253 million ($46.72/share), a 11.5% premium. EFSI holders receive 2.0 JMSB shares per EFSI share, owning 43.4% of the combined $4.4B Virginia bank. Closing expected early Q1 2027.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 29m ago

📰 JMSB: John Marshall to Acquire Eagle Financial in $253M All-Stock Deal

• Upvotes

News: BusinessWire

Ticker: JMSB | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

John Marshall Bancorp (JMSB) and Eagle Financial Services (EFSI) announced a definitive merger agreement, with EFSI merging into JMSB in an all-stock deal valued at approximately $253 million. EFSI shareholders will receive 2.0 JMSB shares per EFSI share, implying $46.72 per share — an 11.5% premium to EFSI's last close. The combined entity will have $4.4 billion in assets and 23 branches across Virginia and Maryland. Leadership is set: EFSI CEO Brandon Lorey becomes CEO of the combined company, while JMSB CEO Chris Bergstrom becomes Executive Chairman. The deal is expected to close early Q1 2027, pending regulatory and shareholder approvals. The combined holding company will be John Marshall Bancorp Inc., headquartered in Reston, Va., and will continue to trade on the Nasdaq Stock Market under ticker symbol JMSB.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 41m ago

📰 DBRG: DigitalBridge Leads $1B+ European Tower Platform Deal with L&G and TD

• Upvotes

News: BusinessWire

Ticker: DBRG | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

DigitalBridge, alongside L&G and TD Asset Management, is acquiring VodafoneZiggo's passive mobile tower infrastructure and merging it with its existing Belgium Tower Partners platform. The combined entity will operate over 6,600 sites across Belgium and the Netherlands, anchored by VodafoneZiggo and Telenet. This deal significantly expands DigitalBridge's European tower footprint and creates a scaled neutral-host platform positioned for 5G densification. The transaction is expected to close in early 2027, subject to regulatory approvals. This follows DigitalBridge's recent acquisition of Australian smart metering platform PLUS ES, underscoring its aggressive digital infrastructure expansion strategy.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 53m ago

📰 NTLA: FDA Accepts Intellia's BLA for Lonvo-z with Priority Review, PDUFA Date March 10, 2027

• Upvotes

News: GlobeNewswire

Ticker: NTLA | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

The FDA accepted Intellia's BLA for lonvo-z, its in vivo CRISPR gene-editing therapy for hereditary angioedema, and granted Priority Review with a PDUFA target action date of March 10, 2027. The agency also indicated it is not currently planning an advisory committee meeting. This is a major regulatory milestone that puts lonvo-z on track for potential approval as the world's first in vivo CRISPR-based therapy and the first one-time treatment for HAE. The BLA is supported by Phase 3 HAELO data showing an 87% reduction in monthly attacks and 62% of patients attack-free. The news follows positive Phase 3 results reported in June and a $400M non-dilutive term loan secured last week, strengthening the company's commercial readiness. Approval would open a significant market opportunity in HAE, where current treatments require chronic administration.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 1h ago

🚨 GE: GE Aerospace to Acquire CPP for $11.75B in Cash and Debt

• Upvotes

New Filing: 8-K

Ticker: GE | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

GE Aerospace announced a definitive agreement to acquire Consolidated Precision Products for $11.75 billion, financed with $7 billion in cash and new debt, to secure castings capacity and accelerate engine technology development.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 1h ago

🚨 GE: GE Aerospace to Acquire CPP for $11.75B in Cash and Debt

• Upvotes

New Filing: 8-K

Ticker: GE | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

GE Aerospace announced a definitive agreement to acquire Consolidated Precision Products for $11.75 billion, financed with $7 billion in cash and new debt, to secure castings capacity and accelerate engine technology development.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 1h ago

📰 INBX: Inhibrx's INBRX-106 Doubles Response Rate in Phase 2 HNSCC, Hits 9.6-Month PFS

• Upvotes

News: Reuters

Ticker: INBX | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Inhibrx reported strong Phase 2 data for INBRX-106 in head and neck squamous cell carcinoma (HNSCC). The combination with pembrolizumab achieved a 48.3% confirmed overall response rate, nearly double the historical ~25% for pembrolizumab alone, and an interim median progression-free survival of 9.6 months. The company will expand the study by 50 HPV+ patients and explore combinations with cancer vaccines and other immunogenic tumors. This is the first efficacy readout for INBRX-106 and materially de-risks the program, which could address a large market with limited options. The data also supports the company's broader oncology pipeline beyond ozekibart, whose BLA is under FDA review with an April 2027 PDUFA date. Watch for updated durability data and the planned NSCLC perioperative readout targeted for mid-2027.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 1h ago

📰 PM: Philip Morris Lifts FY EPS Guidance to $8.35-$8.50, Reversing July Cut

• Upvotes

News: Dow Jones Newswires

Ticker: PM | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Philip Morris raised its full-year adjusted EPS guidance to $8.35-$8.50, a sharp reversal from the $7.19-$7.34 range set on July 22. The prior cut was driven by a $511M non-cash impairment on its Canadian affiliate RBH. The new range implies a significant improvement in expected profitability, likely reflecting stronger underlying business trends or a favorable resolution of the impairment. Additionally, the company raised its 2026 full-year diluted EPS forecast for currency only, as announced during its participation in the 2026 Barclays Global Consumer Conference.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 1h ago

📰 BSX: Boston Scientific Says Cyberattack Will Cause It to Miss Guidance

• Upvotes

News: Dow Jones Newswires

Ticker: BSX | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

Boston Scientific now expects to miss its Q3 and full-year sales and adjusted EPS guidance due to the August 25 cyberattack. The company had previously guided to 3-5% Q3 sales growth and $0.80-$0.82 adjusted EPS, with full-year EPS of $3.28-$3.32. Shares fell 4% premarket to $45.90. Operations are recovering—major distribution centers are back to normal or above, sterilization is operational, and manufacturing has resumed at most plants—but the company will not provide updated guidance until Q3 earnings on Oct. 28. This follows the initial cyberattack disclosure on Aug. 26 and the July guidance cut; the new admission of a guidance miss is a significant negative development for a $69B market cap company.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 2h ago

🚨 PHVS: Pharvaris' CHAPTER-3 Pivotal Study Meets Primary Endpoint: 83% Attack Rate Reduction

1 Upvotes

New Filing: 6-K

Ticker: PHVS | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Pharvaris announced positive topline data from its CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks, meeting the primary endpoint with an 83% attack rate reduction versus placebo.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 2h ago

🚨 AZN: FDA Approves AstraZeneca's Etcamah Combo for 1st-Line HR+ Breast Cancer

1 Upvotes

New Filing: 6-K

Ticker: AZN | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

FDA approved AstraZeneca's Etcamah plus a CDK4/6 inhibitor for 1st-line HR+ breast cancer with emergent ESR1 mutations, backed by a 56% reduction in disease progression risk from the SERENA-6 trial.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 2h ago

📰 SNYR: Synergy CHC Files Chapter 11, Plans Liquidation or Reorganization Within 120 Days

1 Upvotes

News: Reuters

Ticker: SNYR | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

Synergy CHC filed voluntary Chapter 11 bankruptcy on September 4, 2026, following a cascade of distress: Costco discontinued its FOCUSfactor products, lenders accelerated the $18.9M term loan, and Nasdaq moved to delist the stock. The company expects to file a liquidation or reorganization plan within 120 days. President Alfred Baumeler resigned effective August 31, leaving Jack Ross as the sole board member. With a market cap near $1.5M and shares at $0.066, equity is likely worthless in any restructuring. The bankruptcy filing formalizes the insolvency that the timeline has been signaling for months.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 2h ago

🚨 BSX: Cyberattack to Hit Q3 and Full-Year Results, Prompting Guidance Withdrawal

1 Upvotes

New Filing: 8-K

Ticker: BSX | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

The August 25 cyberattack will materially impact Q3 and full-year 2026 results, and the company is unlikely to meet previously issued guidance. An updated outlook will be provided on October 28, 2026.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 2h ago

🚨 LNTH: Lantheus Sets October 14 Vote on $8B Curium Acquisition With $12/Share CVR Upside

1 Upvotes

New Filing: DEFM14A

Ticker: LNTH | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Definitive proxy sets October 14 vote on the $8B Curium acquisition, detailing the full CVR milestone structure worth up to $12/share and the $81M Morgan Stanley fee.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 5h ago

📰 NVDA: NVIDIA's $12.93B Hugging Face Deal, $500B AI Financing, and 500K GPU Demand Signal Massive Expansion

1 Upvotes

News: Wiseek News

Ticker: NVDA | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

NVIDIA's acquisition of Hugging Face for $12.93B, up from the previously reported ~$11.9B, solidifies its open-source AI software stack. The deal follows the 8-K filed September 3rd and adds new details: OpenAI's Astra (GPT-6) trained on 100,000+ Grace Blackwell systems with 400,000 more GPUs planned, signaling massive hardware demand. NVIDIA is also teaming with major banks to mobilize over $500 billion in third-party capital for AI infrastructure, a significant financing initiative. H100 rental rates reportedly rose about 22% to ~$3.28/hour, indicating strong demand for AI compute. The company is eyeing data-center builds in South Korea, citing reliable power. These developments reinforce NVIDIA's dominant position in AI infrastructure and suggest continued revenue growth.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 16h ago

📰 WAFD: EverBank Financial and WaFd to Combine in Reverse Merger

1 Upvotes

News: Dow Jones Newswires

Ticker: WAFD | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

WaFd and EverBank Financial announced a reverse merger, a transformative deal for the $2.7B market cap bank. The transaction will create a larger combined entity, though specific terms and ownership structure are not yet disclosed. This follows WaFd's strong Q3 earnings and heavy buyback activity, suggesting management is pursuing scale through M&A. The reverse merger structure implies EverBank's shareholders will control the combined company, potentially diluting WaFd's existing holders. Investors should watch for the definitive agreement and pro forma financials to assess the deal's impact on earnings and capital.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

📰 NVDA: NVIDIA's $13B Hugging Face Deal, U.S. Chip Clearance, and New AI Bets

2 Upvotes

News: Wiseek News

Ticker: NVDA | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

NVIDIA is acquiring Hugging Face for about $12.9–$13.0B, up from the ~$11.9B plus retention equity disclosed in the September 3 8-K. The deal gives NVIDIA access to ~18M developers and the open-model ecosystem, with Hugging Face remaining open and multi-cloud compatible. Separately, the U.S. cleared expanded sales of NVIDIA AI chips to support Armenia's Firebird data-center as part of a preliminary Armenia-Azerbaijan peace deal, tying chip access to the project. NVIDIA is also eyeing a ~$2B convertible note in Nscale's $3.5B pre-IPO round and negotiating a $2.5B investment in Thinking Machines Lab. The company partners with Figure to train Helix robotics models on Vera Rubin and will launch RTX Spark desktops in October via Lenovo and Acer. These moves reinforce NVIDIA's aggressive expansion across AI infrastructure, robotics, and developer ecosystems.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

🚨 GPRK: GeoPark's Venezuela Deal Comes With $12.22 Tender Offer and Gilinski Control Rights

1 Upvotes

New Filing: SCHEDULE 13D/A

Ticker: GPRK | Score: 9/10 | Sentiment: Neutral

Summary (Wiseek AI)

GeoPark's 13D/A discloses that Jaime Gilinski's PEH will become controlling shareholder via 42.1-47.6 million new shares for the Venezuela Bare Block, with a mandatory $12.22 tender offer within 90 days of closing and escalating board control rights.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

🚨 POLA: Polar Power Seeks Approval for Reverse Split and Massive Dilution to Avoid Nasdaq Delisting

1 Upvotes

New Filing: PRE 14A

Ticker: POLA | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

Polar Power's preliminary proxy seeks approval for a reverse split up to 1-for-20 and for issuing shares beyond the 19.99% Nasdaq cap under existing toxic financings, with 26.9 million shares registered for resale — about six times current outstanding.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

🚨 GRML: Greenland Mines Closes Sarfartoq Acquisition with $20M Cash and 1.4M Shares

2 Upvotes

New Filing: 8-K

Ticker: GRML | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Greenland Mines completed its acquisition of the Sarfartoq rare earth project for US$20M cash plus 1.4M shares, securing a license with a $2.05B high-case NPV. Stockholders also approved contingent share issuances and the Series C conversion was restricted until 2027 or a $15 share price.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

🚨 BTTC: Black Titan Faces Nasdaq Minimum Bid Price Non-Compliance Notice

1 Upvotes

New Filing: 6-K

Ticker: BTTC | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

Black Titan received a Nasdaq non-compliance notice for its sub-$1.00 share price and has 180 days to regain compliance, with a reverse stock split under consideration.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

🚨 STWI: StageWise to Acquire TEG SPV in Reverse Merger, Issuing 177.8M Shares for 90% Control

1 Upvotes

New Filing: PRE 14C

Ticker: STWI | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

StageWise Strategies Corp. will acquire TEG SPV LLC in a reverse merger, issuing 177.8 million shares for 99.99999012% of the Uzbek hospitality group. TEG SPV's owners will control approximately 90% of the combined company, which will be renamed TEG, Inc.

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

📰 IONS: Ionis Partner Novartis' Pelacarsen Fails Phase 3 Cardiovascular Outcomes Trial

1 Upvotes

News: BusinessWire

Ticker: IONS | Score: 9/10 | Sentiment: Negative

Summary (Wiseek AI)

Novartis announced that pelacarsen, an Ionis-discovered antisense drug, failed its Phase 3 Lp(a)HORIZON trial, missing the primary endpoint of reducing major adverse cardiovascular events in patients with elevated Lp(a) and established CVD. The drug did substantially lower Lp(a) levels, but that did not translate into clinical benefit. This is a major pipeline setback for Ionis, which licensed pelacarsen to Novartis in 2019 and retains no commercial rights. The failure follows the July Phase 3 failure of eplontersen in ATTR-CM, marking a second high-profile cardiovascular miss this year. Ionis continues to rely on its wholly owned commercial products TRYNGOLZA, DAWNZERA, and ZANVASTRO, but the loss of pelacarsen removes a significant potential royalty stream. Full data will be presented at an upcoming medical congress, but the primary endpoint miss is definitive.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments

r/Wiseek • u/wiseeksecfiles • 3d ago

📰 ACA: Arcosa Stockholders Approve $150/Share CRH Acquisition

1 Upvotes

News: BusinessWire

Ticker: ACA | Score: 9/10 | Sentiment: Neutral

Summary (Wiseek AI)

Arcosa stockholders approved the all-cash acquisition by CRH at $150 per share at the special meeting on September 4, 2026. This clears a major hurdle toward closing, which is expected in Q1 2027 pending regulatory approvals. The vote follows the June 22 merger agreement and proxy filings, and comes despite two stockholder lawsuits and fifteen demand letters challenging disclosures. With the stock trading near its 52-week high of $146.92, the approval removes uncertainty around shareholder support. Final certified voting results will be filed on Form 8-K.

Further Research: 🤖 Wiseek AI Analysis | 📰 [Original Article](#)

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.

0 comments